Orthofix (OFIX) awards CLO stock options and new RSU grant

Rhea-AI Filing Summary

Orthofix Medical Inc. reported that Chief Legal Officer Jorge Andres Cedron received equity awards in the form of stock options and restricted stock units. On March 3, 2026, he was granted 54,656 employee stock options and 23,024 shares of common stock as a grant/award acquisition.

The restricted stock units vest in equal one-third installments on the first, second, and third anniversaries of the grant date. The options also vest and become exercisable in equal one-third installments on each of the first three anniversaries. Following the stock grant, he directly holds 65,524 shares of common stock, which includes 36,767 previously reported restricted stock units.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Cedron Jorge Andres

Role CLO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	54,656	$0.00	--
Grant/Award	Common Stock	23,024	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 54,656 shares (Direct); Common Stock — 65,524 shares (Direct)

Footnotes (1)

1. Represents a grant of restricted stock units approved by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). The restricted stock units vest with respect to one-third (1/3rd) of the shares of stock covered thereby on the first, second and third anniversary of the Grant Date. Includes 36,767 previously reported restricted stock units. The options vest and become exercisable with respect to one-third (1/3rd) of the shares covered thereby on the first, second and third anniversary of the Grant Date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cedron Jorge Andres

(Last) (First) (Middle)

3451 PLANO PARKWAY

(Street)

LEWISVILLE TX 75056

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orthofix Medical Inc. [ OFIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CLO

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		A		23,024(1)	A	$0	65,524(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$13.03	03/03/2026		A		54,656		(3)	03/03/2033	Common Stock	54,656	$0	54,656	D

Explanation of Responses:

1. Represents a grant of restricted stock units approved by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). The restricted stock units vest with respect to one-third (1/3rd) of the shares of stock covered thereby on the first, second and third anniversary of the Grant Date.

2. Includes 36,767 previously reported restricted stock units.

3. The options vest and become exercisable with respect to one-third (1/3rd) of the shares covered thereby on the first, second and third anniversary of the Grant Date.

	/s/ Jorge Andres Cedron	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Orthofix Medical (OFIX) report for Jorge Andres Cedron?

Orthofix Medical reported that Chief Legal Officer Jorge Andres Cedron received equity awards, not open-market trades. He was granted 54,656 employee stock options and 23,024 shares of common stock as restricted stock units on March 3, 2026, as part of a compensation program.

How many stock options were granted to Orthofix Medical CLO Jorge Andres Cedron?

Cedron received 54,656 employee stock options as a grant on March 3, 2026. These options vest in three equal installments, with one-third becoming exercisable on each of the first, second, and third anniversaries of the grant date under the company’s equity plan.

How many restricted stock units did Jorge Andres Cedron receive from Orthofix Medical?

He received 23,024 shares of common stock in the form of restricted stock units on March 3, 2026. The restricted stock units vest in one-third increments on the first, second, and third anniversaries of the grant date, subject to the plan’s administration and terms.

What is the vesting schedule for Cedron’s new Orthofix restricted stock units and options?

Both the restricted stock units and options vest over three years. One-third of each award vests on the first anniversary of the grant date, another third on the second anniversary, and the remaining third on the third anniversary, creating a multi-year retention structure.

How many Orthofix Medical common shares does Jorge Andres Cedron hold after these grants?

After the March 3, 2026 grant, Cedron directly holds 65,524 shares of Orthofix common stock. This total includes 36,767 previously reported restricted stock units, reflecting both earlier equity awards and the new restricted stock unit grant disclosed in the same insider filing.

Were Cedron’s Orthofix equity awards purchased on the open market?

No, the filing classifies both transactions as grant or award acquisitions at a price of $0.00 per share. They represent compensation-related equity awards—employee stock options and restricted stock units—approved by the Compensation and Talent Development Committee of Orthofix’s Board of Directors.